|
Juberg-Marsidi syndrome
|
|
0.010 |
GeneticVariation
|
BEFREE |
In DNA from biopsies, mosaicism for pathogenic variants, including KRAS p.Ala146Thr in two OES subjects, FGFR1 p.Asn546Lys and KRAS p.Ala146Val in ECCL patients, and KRAS p.Gly12Asp in both SFMS patients, was demonstrated.
|
30891959 |
2019 |
|
Pancreatic carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Importantly, FGTI-2734 inhibited the growth of xenografts derived from four patients with pancreatic cancer with mutant KRAS (2 G12D and 2 G12V) tumors.
|
31227505 |
2019 |
|
Malignant neoplasm of pancreas
|
|
0.010 |
GeneticVariation
|
BEFREE |
Importantly, FGTI-2734 inhibited the growth of xenografts derived from four patients with pancreatic cancer with mutant KRAS (2 G12D and 2 G12V) tumors.
|
31227505 |
2019 |
|
Neuromuscular Diseases
|
|
0.010 |
GeneticVariation
|
BEFREE |
This case emphasizes the fact that HRAS is the only gene responsible for neuromuscular spindle excess, underlines a correlation between p.Gly12Val mutation and severe CS phenotype and points out the importance of a muscle biopsy performed according to the suitable procedure in neuromuscular disorders for any fetal arthrogryposis.
|
28455154 |
2017 |
|
Myeloproliferative disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
Further, one of the patients (c.35G>A; p.(Gly12Asp)) had a myeloproliferative disorder, and one subject (c.34G>C; p.(Gly12Arg)) exhibited an uncharacterized brain tumour.
|
28594414 |
2017 |
|
Chronic myeloproliferative disorder
|
|
0.010 |
GeneticVariation
|
BEFREE |
Further, one of the patients (c.35G>A; p.(Gly12Asp)) had a myeloproliferative disorder, and one subject (c.34G>C; p.(Gly12Arg)) exhibited an uncharacterized brain tumour.
|
28594414 |
2017 |
|
Arthrogryposis
|
|
0.010 |
GeneticVariation
|
BEFREE |
This case emphasizes the fact that HRAS is the only gene responsible for neuromuscular spindle excess, underlines a correlation between p.Gly12Val mutation and severe CS phenotype and points out the importance of a muscle biopsy performed according to the suitable procedure in neuromuscular disorders for any fetal arthrogryposis.
|
28455154 |
2017 |
|
Carcinoma of lung
|
|
0.010 |
GeneticVariation
|
BEFREE |
Since hypoxic microenvironments select for tumor cells with diminished therapeutic response, we investigated whether hypoxia unequally increases resistance to 3-BrPA in wt p53 MelJuso melanoma harbouring (Q61L)-mutant NRAS and wt BRAF, C8161 melanoma with (G12D)-mutant KRAS (G464E)-mutant BRAF, and A549 lung carcinoma with a KRAS (G12S)-mutation.
|
27863474 |
2016 |
|
Ductal Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
We employed the sensitive and quantitative Allele-specific Competitive Blocker PCR approach to characterize mutant cancer subpopulations in ductal carcinomas (DCs), examining five specific hotspot point mutations (PIK3CA H1047R, KRAS G12D, KRAS G12V, HRAS G12D, and BRAF V600E).
|
27108388 |
2016 |
|
Precancerous Conditions
|
|
0.010 |
GeneticVariation
|
BEFREE |
In sst2+/- mice, PI3K was activated and signaled via AKT (PKB; protein kinase B); when these mice were crossed with KRAS(G12D) mice, premalignant lesions, tumors, and lymph node metastases developed more rapidly than in KRAS(G12D) mice.
|
25683115 |
2015 |
|
Secondary malignant neoplasm of lymph node
|
|
0.010 |
GeneticVariation
|
BEFREE |
In sst2+/- mice, PI3K was activated and signaled via AKT (PKB; protein kinase B); when these mice were crossed with KRAS(G12D) mice, premalignant lesions, tumors, and lymph node metastases developed more rapidly than in KRAS(G12D) mice.
|
25683115 |
2015 |
|
Non-Small Cell Lung Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
A doxycycline-inducible mouse model of KRAS (G12D) driven NSCLC and patient data was analyzed from multiple publicly accessible databases including TCGA, CCLE, NCBI GEO and Project Achilles.
|
26173780 |
2015 |
|
Childhood Leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
We successfully established a mouse model of human leukemia by transplanting bone marrow cells co-transfected with the K-ras (G12D) mutation and AML1/ETO fusion protein.
|
24480914 |
2014 |
|
Adult Acute Monoblastic Leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Co-transduction of Kras(G12D) and AML1/ETO induces acute monoblastic leukemia.
|
24480914 |
2014 |
|
Acute monocytic leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Co-transduction of Kras(G12D) and AML1/ETO induces acute monoblastic leukemia.
|
24480914 |
2014 |
|
Seborrheic keratosis
|
|
0.010 |
GeneticVariation
|
BEFREE |
In addition, 1 SK revealed the KRAS p.G12V mutation, which has already been reported in SK.
|
23739246 |
2014 |
|
Papilloma
|
|
0.010 |
GeneticVariation
|
BEFREE |
Hras(G12V) allele copy number was increased in all papillomas induced by TPA.
|
24240680 |
2014 |
|
leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
We successfully established a mouse model of human leukemia by transplanting bone marrow cells co-transfected with the K-ras (G12D) mutation and AML1/ETO fusion protein.
|
24480914 |
2014 |
|
Acute monoblastic leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Co-transduction of Kras(G12D) and AML1/ETO induces acute monoblastic leukemia.
|
24480914 |
2014 |
|
Childhood Acute Monoblastic Leukemia
|
|
0.010 |
GeneticVariation
|
BEFREE |
Co-transduction of Kras(G12D) and AML1/ETO induces acute monoblastic leukemia.
|
24480914 |
2014 |
|
Esophageal Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
We developed two mouse models of esophageal cancer by inoculating immunocompetent mice with syngeneic esophageal cell lines transformed by cyclin-D1 or mutant HRAS(G12V) and loss of p53.
|
21869822 |
2011 |
|
Tumor Progression
|
|
0.010 |
GeneticVariation
|
BEFREE |
The transformed phenotype of IOE(CMYC) cells was further enhanced in concert with KRAS(G12V)/BRAF(V600E) expression, as in vitro analyses indicated that IOE(CMYC) cells had undergone morphological and phenotypic changes characteristic of neoplastic progression.
|
21859834 |
2011 |
|
Malignant neoplasm of esophagus
|
|
0.010 |
GeneticVariation
|
BEFREE |
We developed two mouse models of esophageal cancer by inoculating immunocompetent mice with syngeneic esophageal cell lines transformed by cyclin-D1 or mutant HRAS(G12V) and loss of p53.
|
21869822 |
2011 |
|
Thymic Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
One thymoma and one thymic carcinoma harbored KRAS mutations (G12A and G12V, respectively), and one thymoma had a G13V HRAS mutation.
|
19861435 |
2009 |
|
Thymoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
One thymoma and one thymic carcinoma harbored KRAS mutations (G12A and G12V, respectively), and one thymoma had a G13V HRAS mutation.
|
19861435 |
2009 |